Fortress Biotech, Inc.
No enriched coverage for $FBIOP in the last 7 days.
No SEC Form 4 filings for $FBIOP in the last 30 days.
See all $FBIOP insider activity →Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Fortress Biotech, Inc._June 17, 2026 0001429260 false 0001429260 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2026-06-17 2026-06-17 0001429260 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANG
Fortress Biotech’s (NASDAQ: FBIOP) shares rose 5.2% on Monday, trading between $20.70 and $20.48 versus a prior close of $19.47, according to market data. Volume was about 105,677 shares, up 345% from the average 23,769. The stock is above its 50-day ($14.56) and 200-day ($11.96) moving averages.
This article provides details about Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) on the Nasdaq Stock Market. It briefly mentions the availability of financial data, news, community insights, and technical analysis for this specific stock. The content seems to be a snapshot of a financial data platform's entry for FBIOP, showing it's publicly traded and offers various analytical tools.
Recent FBIOP coverage spans financial news, corporate actions and market movers.
Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Fortress Biotech, Inc._June 17, 2026 0001429260 false 0001429260 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2026-06-17 2026-06-17 0001429260 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANG
The article provides a same-session price/volume surge and moving-average context, but no new fundamental catalyst.
The preferred stock FBIOP shows minimal immediate trading impact due to its low relevance score and niche market segment.
Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This PRV was issued following the FDA approval of ZYCUBO for Menkes disease, with Sentynl Therapeutics having assumed responsibility for its development and commercialization. Cyprium is also eligible for royalties and milestones from Sentynl, and will pay 20% of the PRV proceeds to the NIH.
Fortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
alphai scores every news story that mentions FBIOP with an AI model for sentiment and relevance, and aggregates insider trades from Fortress Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Fortress Biotech, Inc._June 17, 2026 0001429260 false 0001429260 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2026-06-17 2026-06-17 0001429260 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANG
2 min readFortress Biotech’s (NASDAQ: FBIOP) shares rose 5.2% on Monday, trading between $20.70 and $20.48 versus a prior close of $19.47, according to market data. Volume was about 105,677 shares, up 345% from the average 23,769. The stock is above its 50-day ($14.56) and 200-day ($11.96) moving averages.
2 min readThis article provides details about Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) on the Nasdaq Stock Market. It briefly mentions the availability of financial data, news, community insights, and technical analysis for this specific stock. The content seems to be a snapshot of a financial data platform's entry for FBIOP, showing it's publicly traded and offers various analytical tools.
2 min readFortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This PRV was issued following the FDA approval of ZYCUBO for Menkes disease, with Sentynl Therapeutics having assumed responsibility for its development and commercialization. Cyprium is also eligible for royalties and milestones from Sentynl, and will pay 20% of the PRV proceeds to the NIH.
3 min readFortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readTotal net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of ...
4 min readFDA-approved Emrosi ( 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release ) is available in the United States for the treatment of inflammatory lesions of rosacea in adults
2 min readLOS ANGELES, Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Fortress Biotech Inc., ( "Slide" or the "Company" ) ( NASDAQ:FBIO ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
2 min readDotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad
4 min readDotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy ...
3 min read
